Passive exercise using whole-body periodic acceleration enhances blood supply to ischemic hindlimb

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 31, Issue 12, 2011, Pages 2872-2880

  Rokutanda, Taku ^a   Izumiya, Yasuhiro ^a   Miura, Mitsutoshi ^a   Fukuda, Shota ^b   Shimada, Kenei ^c   Izumi, Yasukatsu ^c   Nakamura, Yasuhiro ^c   Araki, Satoshi ^a   Hanatani, Shinsuke ^a   Matsubara, Junichi ^a   Nakamura, Taishi ^a   Kataoka, Keiichiro ^a   Yasuda, Osamu ^a   Kaikita, Koichi ^a   Sugiyama, Seigo ^a   Kim Mitsuyama, Shokei ^a   Yoshikawa, Junichi ^d   Fujita, Masatoshi ^e   Yoshiyama, Minoru ^c   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Osaka Ekisaikai Hospital   (Japan)

^c OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Nishinomiya Watanabe Cardiovascular Center   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenesis; endothelial function; exercise; peripheral arterial disease; vascular biology

Indexed keywords

ANGIOGENIC FACTOR; ANTIBODY; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD31 ANTIBODY; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR; STROMAL CELL DERIVED FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME PHOSPHORYLATION; EXERCISE; HUMAN; LEG BLOOD FLOW; LEG ISCHEMIA; LEG REVASCULARIZATION; MALE; MOUSE; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; WHOLE BODY PERIODIC ACCELERATION;

ACCELERATION; AGED; ANIMALS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HINDLIMB; HUMANS; ISCHEMIA; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MOTION THERAPY, CONTINUOUS PASSIVE; MUSCLE, SKELETAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE TYPE III; PERIPHERAL ARTERIAL DISEASE; PHYSICAL CONDITIONING, ANIMAL; PROTO-ONCOGENE PROTEINS C-SIS; REGIONAL BLOOD FLOW; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 81755174321     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.229773     Document Type: Article

References (43)

1. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;47:1239-1312.
2. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347:1941-1951.
3. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain: a meta-analysis. JAMA. 1995;274: 975-980.
4. Brass EP, Hiatt WR, Green S. Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a pointcounterpoint discussion. Vasc Med. 2004;9:293-301. (Pubitemid 40202246)
5. Gustafsson T, Puntschart A, Kaijser L, Jansson E, Sundberg CJ. Exerciseinduced expression of angiogenesis-related transcription and growth factors in human skeletal muscle. Am J Physiol. 1999;276:H679-H685. (Pubitemid 29100638)
6. Hoppeler H. Vascular growth in hypoxic skeletal muscle. Adv Exp Med Biol. 1999;474:277-286.
7. Adams JA. Endothelium and cardiopulmonary resuscitation. Crit Care Med. 2006;34:S458-S465. (Pubitemid 44772682)
8. Kohler M, Amann-Vesti BR, Clarenbach CF, Brack T, Noll G, Russi EW, Bloch KE. Periodic whole body acceleration: a novel therapy for cardiovascular disease. Vasa. 2007;36:261-266. (Pubitemid 350260420)
9. Matsumoto T, Fujita M, Tarutani Y, Yamane T, Takashima H, Nakae I, Horie M. Whole-body periodic acceleration enhances brachial endothelial function. Circ J. 2008;72:139-143. (Pubitemid 351413342)
10. Fukuda S, Shimada K, Kawasaki T, Kono Y, Jissho S, Taguchi H, Maeda K, Yoshiyama M, Fujita M, Yoshikawa J. "Passive exercise" using whole body periodic acceleration: effects on coronary microcirculation. Am Heart J. 2010;159:620-626.
11. Sackner MA, Gummels E, Adams JA. Nitric oxide is released into circulation with whole-body, periodic acceleration. Chest. 2005;127: 30-39. (Pubitemid 41724552)
12. Adams JA, Bassuk J, Wu D, Grana M, Kurlansky P, Sackner MA. Periodic acceleration: effects on vasoactive, fibrinolytic, and coagulation factors. J Appl Physiol. 2005;98:1083-1090. (Pubitemid 40283693)
13. Patsouris D, Li PP, Thapar D, Chapman J, Olefsky JM, Neels JG. Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals. Cell Metab. 2008;8:301-309.
14. Ouchi N, Oshima Y, Ohashi K, Higuchi A, Ikegami C, Izumiya Y, Walsh K. Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem. 2008;283:32802-32811.
15. Izumiya Y, Hopkins T, Morris C, Sato K, Zeng L, Viereck J, Hamilton JA, Ouchi N, LeBrasseur NK, Walsh K. Fast/glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab. 2008;7:159-172. (Pubitemid 351168553)
16. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res. 2002;43:805-814. (Pubitemid 34477908)
17. Wu H, Jin Y, Arias J, Bassuk J, Uryash A, Kurlansky P, Webster K, Adams JA. In vivo upregulation of nitric oxide synthases in healthy rats. Nitric Oxide. 2009;21:63-68.
18. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567-2578. (Pubitemid 28270451)
19. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287: 2570-2581. (Pubitemid 34517204)
20. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007;101:948-956. (Pubitemid 350287182)
21. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes. 2007;56: 656-665. (Pubitemid 46348460)
22. Shoji T, Koyama H, Morioka T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y. Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes. Diabetes. 2006;55:2245-2255. (Pubitemid 44743621)
23. Tanii M, Yonemitsu Y, Fujii T, Shikada Y, Kohno R, Onimaru M, Okano S, Inoue M, Hasegawa M, Onohara T, Maehara Y, Sueishi K. Diabetic microangiopathy in ischemic limb is a disease of disturbance of the platelet-derived growth factor-BB/protein kinase C axis but not of impaired expression of angiogenic factors. Circ Res. 2006;98:55-62. (Pubitemid 43970203)
24. Nelson ME, Rejeski WJ, Blair SN, Duncan PW, Judge JO, King AC, Macera CA, Castaneda-Sceppa C. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation. 2007;116: 1094-1105. (Pubitemid 47329573)
25. Hoier B, Rufener N, Bojsen-Moller J, Bangsbo J, Hellsten Y. The effect of passive movement training on angiogenic factors and capillary growth in human skeletal muscle. J Physiol. 2010;588:3833-3845.
26. Ballaz L, Fusco N, Cretual A, Langella B, Brissot R. Acute peripheral blood flow response induced by passive leg cycle exercise in people with spinal cord injury. Arch Phys Med Rehabil. 2007;88:471-476. (Pubitemid 46482436)
27. Ter Woerds W, De Groot PC, Van Kuppevelt DH, Hopman MT. Passive leg movements and passive cycling do not alter arterial leg blood flow in subjects with spinal cord injury. Phys Ther. 2006;86:636-645.
28. Adams JA, Mangino MJ, Bassuk J, Kurlansky P, Sackner MA. Regional blood flow during periodic acceleration. Crit Care Med. 2001;29: 1983-1988. (Pubitemid 32980412)
29. Miyamoto S, Fujita M, Inoko M, Oba M, Hosokawa R, Haruna T, Izumi T, Saji Y, Nakane E, Abe T, Ueyama K, Nohara R. Effect on treadmill exercise capacity, myocardial ischemia, and left ventricular function as a result of repeated whole-body periodic acceleration with heparin pretreatment in patients with angina pectoris and mild left ventricular dysfunction. Am J Cardiol. 2011;107:168-174.
30. Braith RW, Conti CR, Nichols WW, Choi CY, Khuddus MA, Beck DT, Casey DP. Enhanced external counterpulsation improves peripheral artery flow-mediated dilation in patients with chronic angina: a randomized sham-controlled study. Circulation. 2010;122:1612-1620.
31. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250. (Pubitemid 34787405)
32. Hiasa K, Ishibashi M, Ohtani K, Inoue S, Zhao Q, Kitamoto S, Sata M, Ichiki T, Takeshita A, Egashira K. Gene transfer of stromal cell-derived factor-1f enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthaserelated pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation. 2004;109:2454-2461. (Pubitemid 38679567)
33. Benoit H, Jordan M, Wagner H, Wagner PD. Effect of no, vasodilator prostaglandins, and adenosine on skeletal muscle angiogenic growth factor gene expression. J Appl Physiol. 1999;86:1513-1518. (Pubitemid 29230293)
34. Jozkowicz A, Cooke JP, Guevara I, Huk I, Funovics P, Pachinger O, Weidinger F, Dulak J. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res. 2001;51: 773-783. (Pubitemid 32800719)
35. Kim F, Pham M, Maloney E, Rizzo NO, Morton GJ, Wisse BE, Kirk EA, Chait A, Schwartz MW. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset of peripheral insulin resistance. Arterioscler Thromb Vasc Biol. 2008;28:1982-1988.
36. Rizzo NO, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S, Daum G, Handa P, Schwartz MW, Kim F. Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler Thromb Vasc Biol. 2010;30:758-765.
37. Hsu MF, Meng TC. Enhancement of insulin responsiveness by nitric oxide-mediated inactivation of protein-tyrosine phosphatases. J Biol Chem. 2010;285:7919-7928.
38. Walsh K. Adipokines, myokines and cardiovascular disease. Circ J. 2009;73:13-18.
39. Takahashi A, Kureishi Y, Yang J, Luo Z, Guo K, Mukhopadhyay D, Ivashchenko Y, Branellec D, Walsh K. Myogenic Akt signaling regulates blood vessel recruitment during myofiber growth. Mol Cell Biol. 2002; 22:4803-4814. (Pubitemid 34620415)
40. Olfert IM, Howlett RA, Wagner PD, Breen EC. Myocyte vascular endothelial growth factor is required for exercise-induced skeletal muscle angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2010;299: R1059-R1067.
41. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med. 2003;9:604-613. (Pubitemid 36597108)
42. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141: 1659-1673. (Pubitemid 28309179)
43. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652. (Pubitemid 24242728)